Guardant Health (GH) said Wednesday that its Shield blood test has been included in the American Cancer Society's updated Colorectal Cancer Screening guidelines.
The guidelines recommend Shield as an option for patients who decline or have not completed stool-based or visual examination screening tests for colorectal cancer, the company said.
Shares of the company were up 4% in Wednesday's premarket activity.